Small-Molecule IL-4 Inhibitors for Broad Inflammatory Disease Coverage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutics targeting interleukin-4 (IL-4) are inadequate in addressing the dysregulation of cellular signaling associated with inflammatory conditions and its role in autoimmunity, allergic reactions, arthritis, and cancer progression.
Innovation Solution
Development of small molecule inhibitors, such as compounds of formula (I), which selectively target IL-4 receptors to inhibit IL-4 activity, thereby modulating downstream signaling pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutics are used to target IL-4, then treatment is provided for some inflammatory conditions, but the dysregulation of cellular signaling associated with autoimmunity, allergic reactions, arthritis, and cancer progression is not adequately addressed
Solution Approach 1:
The patent develops small molecule inhibitors that can broadly inhibit IL-4 signaling across multiple disease contexts (autoimmunity, allergic reactions, arthritis, cancer) through a single therapeutic mechanism, making the treatment universally applicable to diverse IL-4-mediated conditions while maintaining reliable therapeutic effectiveness
2Reliability
If small molecule inhibitors are developed to selectively target IL-4 receptors, then specific inhibition of IL-4 activity is achieved, but the complexity of the chemical structure and synthesis increases
Solution Approach 1:
The patent optimizes specific molecular parameters (substituent positions, ring structures, molecular weight) of the small molecule inhibitors to achieve selective binding to IL-4 receptors while controlling structural complexity, allowing high selectivity without excessive molecular complexity
3Reliability
If small molecule inhibitors are developed to target IL-4, then therapeutic benefits in treating IL-4 associated diseases are provided, but the cost and time of drug development increases
Solution Approach 1:
The patent performs preliminary structure-activity relationship (SAR) studies and computational modeling to pre-identify promising molecular scaffolds and optimize key structural features before full-scale synthesis and testing, reducing the overall development time while maintaining therapeutic benefit
Data Source
AI summary
Dysregulated IL-4 signaling contributes to a number of immune-mediated diseases such as allergic inflammation, cancer, and autoimmunity. The present disclosure provides small molecule binders and inhibitors of IL-4, and pharmaceutical compositions, kits, and uses thereof.